KEY POINTS
- UnitedHealth reported adjusted EPS of $7.23 versus $6.57 expected on revenue of $111.72 billion, beating estimates by 10% on the bottom line.
- The medical benefit ratio improved to 83.9% from 84.8% a year ago, signaling that the worst of the medical cost pressure cycle has passed.
- Management raised 2026 adjusted EPS guidance to above $18.25, up from $17.75, and authorized at least $2 billion in buybacks by end of Q2.
UnitedHealth Group shares surged 8.75% on Tuesday after the nation's largest health insurer delivered a first-quarter earnings beat that hit every metric Wall Street cares about — revenue, earnings, medical costs, and forward guidance — in a single morning.
The numbers were unambiguous. Adjusted earnings per share came in at $7.23 against a consensus estimate of $6.57, a 10% beat. Revenue reached $111.72 billion versus $109.57 billion expected. Net income hit $6.28 billion, or $6.90 per share on a GAAP basis. Every major segment contributed, and the quarter contained none of the one-time items that can inflate headline numbers while masking underlying weakness.
The Medical Cost Ratio Is the Story
For healthcare investors, the most important line in the report was not the earnings beat but the medical benefit ratio: 83.9% for the quarter, down from 84.8% in the year-earlier period and better than analyst expectations. That ratio — the percentage of premium revenue spent on actual medical claims — is the single best indicator of pricing power versus cost trends in managed care.
The improvement signals that the elevated utilization trends that plagued the sector through 2024 and 2025 are moderating. UnitedHealth's scale gives it better visibility into utilization patterns than any other insurer, so when its medical cost ratio improves, it tends to be a leading indicator for the rest of the managed care complex. Expect Elevance Health, Humana, and Cigna to trade with a positive bias heading into their own reports.
The ratio also matters for the broader market because healthcare spending is the single largest component of consumer services inflation. A stabilizing medical cost environment removes one inflationary pressure point at exactly the moment when energy-driven inflation is dominating the macro picture.
Capital Returns Accelerate
Management raised full-year 2026 adjusted EPS guidance to above $18.25, up from the previous floor of $17.75 — a $0.50 increase that exceeds the Q1 beat, implying confidence in the trajectory for the remaining three quarters. The company also announced plans to repurchase at least $2 billion in shares by the end of Q2, an acceleration of its buyback cadence.
On the strategic front, UnitedHealth agreed to acquire Alegeus Technologies, a healthcare benefits administration platform, expected to close in the second half of 2026. The company also completed the sale of its Optum UK business for approximately $400 million in net proceeds, continuing a portfolio optimization strategy that prioritizes domestic scale over international diversification.
What the Chart Says
The 8.75% move took UNH to $351.76, its best single-session performance since the post-pandemic recovery. The stock had been under pressure for months as investors worried about utilization trends and the political risk of healthcare regulation. Tuesday's move recaptured the 50-day moving average and puts the stock within striking distance of $370, which represents the pre-sell-off resistance level from January.
Volume was roughly 2.5 times the 20-day average, confirming institutional participation in the move. The options market repriced meaningfully, with implied volatility dropping on calls and rising on puts as the risk profile shifted from "broken stock with fundamental concerns" to "earnings inflection with management credibility."
For the Dow specifically, UnitedHealth's 8.75% gain was the single largest contributor to the index's attempt to hold the 49,000 level. The stock's weighting in the price-weighted Dow means its moves have outsized index impact, and Tuesday's surge offset the combined drag from Merck, Honeywell, and Apple declines.
The next catalyst for UNH is the Q2 medical cost ratio, which will confirm or deny whether the Q1 improvement was seasonal or structural. Watch the company's commentary on Medicare Advantage enrollment trends at the JPMorgan Healthcare Conference in May. If the favorable cost trajectory holds through mid-year, the raised guidance floor of $18.25 becomes the new consensus starting point, and the stock has room to $400 by year-end.
